Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results

Key Points

• Tonix reported EPS of ($3.59) for the quarter, matching consensus, while booking a negative net margin of 828.22% and a negative ROE of 57.93%.
• Shares traded down 0.9% to $16.84 (market cap ≈ $147.6M), trading far below the consensus price target of $70 and well off its 52‑week high of $130, highlighting significant volatility.
• Analyst sentiment has shifted bearish with firms like Weiss and Wall Street Zen on "sell" while the consensus remains "Hold," and institutional investors now own 82.26% of the stock.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($3.59) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($3.59), Zacks reports. Tonix Pharmaceuticals had a negative net margin of 828.22% and a negative return on equity of 57.93%.

Tonix Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ:TNXP traded down $0.16 during trading on Monday, reaching $16.84. 498,354 shares of the company traded hands, compared to its average volume of 1,293,405. The firm has a market capitalization of $147.62 million, a PE ratio of -0.43 and a beta of 1.79. Tonix Pharmaceuticals has a 52 week low of $6.76 and a 52 week high of $130.00. The company's 50 day moving average is $23.00 and its two-hundred day moving average is $31.14.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen lowered Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $70.00.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of TNXP. Legal & General Group Plc bought a new position in Tonix Pharmaceuticals in the 2nd quarter valued at about $25,000. BNP Paribas Financial Markets bought a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth approximately $65,000. New York State Common Retirement Fund acquired a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth approximately $104,000. JPMorgan Chase & Co. bought a new position in Tonix Pharmaceuticals in the second quarter valued at approximately $129,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Tonix Pharmaceuticals in the second quarter valued at approximately $149,000. Institutional investors own 82.26% of the company's stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.